FDA Warning Letter

Regulatory Event

On June 2, 2026, FDA issued Warning Letter 320-26-86 to Gopaldas Visram & Co., Ltd., an OTC drug product manufacturer located in Navi Mumbai, Maharashtra, India, citing failures that cut to the core of what pharmaceutical laboratory controls are designed to prevent. The letter, issued by the Center for Drug Evaluation and Research’s (CDER) Office of Manufacturing Quality, identified two primary violations: first, the quality unit’s failure to ensure that IR (Infrared) spectroscopy methods used for component identity testing — including the critical absence-of-asbestos evaluation required for talc-containing drug products — were scientifically sound and supported by adequate data; and second, the release of component lots that did not meet identity specifications. Taken together, these violations mean that the firm was manufacturing and potentially distributing OTC drug products containing a component that had never been properly confirmed to be free of asbestos, a known human carcinogen.

The specific product context matters here. Gopaldas Visram manufactures OTC drug products formulated to contain talc as an inactive ingredient. Talc is a USP (United States Pharmacopeia)-recognized article. Its use is not inherently problematic, but it carries a regulatory obligation that other inactive ingredients do not: the current USP monograph for talc includes specific testing requirements for the absence of asbestos, assessed via IR spectroscopy with defined wavenumber ranges and scale expansions. That test exists because asbestos — specifically the fibrous silicate minerals of the serpentine and amphibole groups — can be present as a natural contaminant in talc mineral deposits, and because the products containing talc can be applied to areas of the body where inadvertent inhalation or tissue exposure creates a carcinogenic risk. FDA’s enforcement posture on talc-containing products has been unequivocal since at least the early 2010s: if you manufacture a product that uses talc, your testing system must be capable of detecting asbestos, and your records must demonstrate that the detection is occurring on an instrument configured and operated correctly for that purpose.

What FDA found at Gopaldas Visram was the opposite. The IR instrument reports submitted for talc lot identity testing did not specify the wavenumbers of peak maxima as required by the USP monograph. The spectral scans did not include scale expansions at the wavenumber ranges specified in the USP method for asbestos evaluation — ranges that are required precisely because the IR signals associated with asbestos mineral contamination appear in specific, narrow spectral windows that an inappropriately scaled or truncated scan will not resolve. For one talc component lot, IR data identified no maxima at all on the scan scale provided, while the USP specification requires identification of maxima at three specific wavenumber positions. For the most recent talc lot in the submitted records, the spectral data showed no maxima whatsoever. These are not interpretation questions or borderline compliance issues; they represent test results that are plainly non-conforming to the USP identification specification, which the firm’s own QU was required to evaluate and reject under 21 CFR 211.160(b).

What the Record Documents

The finding that is likely to draw the most attention from practitioners — and that should — is the observation that IR spectral data for two independently collected talc samples showed wavenumber values identical to three decimal places. This is not a normal outcome for independently acquired IR spectra, even for samples drawn from the same lot under controlled conditions. Instrument noise, baseline variation, sample preparation geometry, and scan-to-scan measurement uncertainty collectively ensure that spectral peak positions, measured to the resolution of a modern Fourier-transform IR spectrometer, will vary at the third decimal place across independent acquisitions. Statistically identical values across independently collected samples raise a direct question about whether the reported spectra were independently generated at all. FDA noted that this finding “raises concerns regarding the authenticity of the reported results.” Under the ALCOA+ (Attributable, Legible, Contemporaneous, Original, Accurate, Complete, Consistent, Enduring, Available) framework that governs pharmaceutical data integrity, the Originality and Accuracy attributes require that each reported record represent an independent, instrument-generated data point — not a transcription, duplicate, or fabrication of a prior result. The firm’s failure to investigate this discrepancy, which FDA cited as a violation of 21 CFR 211.192, compounds the underlying analytical deficiency into a data quality question that will need to be answered as part of any credible remediation.

Understanding why this pattern occurs in talc testing requires understanding how IR spectroscopy for identity and asbestos absence works in practice. The USP talc monograph requires not only a confirmation of the talc mineral identity by IR — matching the spectrum to a reference library spectrum at defined peak positions — but also specific scale expansions in the regions where asbestos minerals produce characteristic absorption bands. Without those scale expansions, the test is incomplete even if the basic identity confirmation appears to pass. A broad-scale IR scan that covers 4000 to 400 cm-1 will show the dominant silicate framework peaks of talc clearly, but the contributions from asbestos mineral contaminants at lower abundances are resolved only when the spectral region of interest is expanded and the baseline carefully evaluated. A firm that does not configure its IR acquisition method to capture these expansions, or that outsources its testing to a contract laboratory that does not operate the method correctly, has created a systematic gap between its written specifications and its actual testing practice — exactly the gap that 21 CFR 211.160(b) is designed to close.

The oversight failure involving the contract testing laboratory compounds the QU failure. FDA explicitly noted that the quality unit did not adequately review or approve the methods used by the contract laboratory, and did not ensure that the contract facility was testing according to procedures that required following current USP specifications. This is a pattern with a clear regulatory footprint: the Mylan Pharmaceuticals Warning Letter of 2011, issued to the Morgantown, West Virginia facility, documented systemic failures in OOS investigation where root causes were cited without evidentiary support — the same pattern of QU oversight failure producing analytical conclusions that lacked adequate documentation. In the Gopaldas Visram case, the QU approval of records that visibly failed to meet USP spectral requirements, and that showed the statistical anomaly of identical decimal-place values across independent samples, represents a QU that had either not reviewed the records in meaningful depth or was approving records that it had reviewed and found acceptable despite non-conformance. Both outcomes are violations of 21 CFR 211.22.

Technical and Quality Context

The second observation — release of a component lot that did not meet the identity specification — follows directly from the first. Gopaldas Visram released a talc component lot for which the IR spectral data submitted showed only two wavenumber maxima identified, while the USP specification requires maxima at three wavenumber positions. The standard used for comparison also showed only two maxima, which raises the additional question of whether the reference standard itself had been adequately qualified. Under 21 CFR 211.84(d)(2), identity testing for each lot of a component must be performed before that component is used in production, and the result must conform to the written specification. The absence of the third required maximum is an identity test failure, not a borderline result — and releasing a component lot against a failing identity test constitutes an adulteration finding under section 501(a)(2)(B) of the FD&C Act, exactly as FDA states in this Warning Letter.

The remediation path here is more involved than it might appear at first. The immediate corrective action FDA has required includes retention sample testing for all implicated talc-containing component lots within 30 days, a retrospective independent review of all component testing results for US products over the past three years, and a comprehensive investigation into the data discrepancies in the IR spectral records. The last item is critical: before Gopaldas Visram can credibly represent to FDA that its analytical controls are now adequate, it must explain the statistically identical IR spectral values. If that investigation reveals that the records were generated improperly — whether by transcription, duplication, or method error — the scope of the retrospective review will expand accordingly.

A company facing this pattern of findings would benefit from a structured remediation approach covering three parallel tracks: a QU systems assessment to establish that the quality unit is resourced and empowered to perform meaningful technical review of laboratory records; an analytical method rebuild that establishes USP-conforming IR acquisition parameters for talc testing, validated against a certified asbestos reference standard; and a contract laboratory qualification audit that confirms the external testing facility is operating methods identical to the sponsor’s approved specifications. The third track is frequently underestimated in scope. Contract laboratory qualification is not a documentation exercise — it requires side-by-side method verification, equipment calibration confirmation, and a technical assessment of the laboratory’s specific IR instrument capability for the talc asbestos absence test. At XGene Consulting, we work with manufacturers at this stage to design the analytical method gap assessment and the contract laboratory qualification protocol, ensuring that the rebuilt testing program will satisfy FDA’s reinspection standard rather than simply meeting a paper requirement.

Decision Relevance

The Gopaldas Visram Warning Letter is a reminder that laboratory controls for component testing — particularly for safety-critical components with carcinogenic contamination risks — are not administrative functions. The IR spectroscopy test for talc asbestos absence exists because the consequence of failure is patient exposure to a human carcinogen. A QU that treats this test as a checkbox, and a contract laboratory program that functions without genuine technical oversight, will eventually produce exactly this outcome: records that cannot be interpreted, lots that should not have been released, and a Warning Letter that exposes the gap between the firm’s documented quality system and its actual analytical practice. The practitioners who avoid this outcome are those who treat method adequacy verification as a continuous QU responsibility, not a one-time validation event.

If you are managing component testing programs for talc-containing products, or overseeing contract laboratory qualification for OTC drug products manufactured at international sites, I welcome the conversation. Connect with me on LinkedIn or visit xgeneconsulting.com to discuss your specific program.